Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Real-world outcomes of HER2+ and TNBC patients recieving neoadjuvant chemotherapy

Bernardo Rapoport • 12 Mar 2021
BCC 2021
Breast Cancer Trastuzumab

Bernardo Leon Rapoport, MD, The Medical Oncology Centre of Rosebank, Johannesburg, & Department of Immunology, University of Pretoria, Pretoria, South Africa, discusses the real-world outcomes of HER2+ and triple-negative breast cancer (TNBC) patients who were treated with neoadjuvant chemotherapy. The results of this retrospective analysis demonstrate that TNBC and HER2+ subsets are associated with a higher pathological complete response, with the real-world results being similar to those reported in clinical trial settings. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

More from Bernardo Rapoport

Side effects associated with checkpoint inhibitor therapies
1:42
Side effects associated with checkpoint inhibitor therapies
Bernardo Rapoport • 23 Jun 2016
Immune adverse events of checkpoint inhibitors
3:05
Immune adverse events of checkpoint inhibitors
Bernardo Rapoport • 23 Jun 2016
Future direction for cancer immunotherapy
1:53
Future direction for cancer immunotherapy
Bernardo Rapoport • 23 Jun 2016
Side effect profile of checkpoint inhibitors
1:18
Side effect profile of checkpoint inhibitors
Bernardo Rapoport • 23 Jun 2016

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals